Summary: In vitro drug metabolism techniques with human CYP c-DNA expressed systems are frequently used to predict human drug metabolism in vivo. The aim of this study was to compare midazolam enzyme kinetics in recombinant expressed CYP3A4 microsomes from human and insect cells. The amounts of 1?-hydroxymidazolam and 4-hydroxymidazolam formed in CYP3A4 microsomes from transfected human liver epithelial cells (T5-3A4 microsomes) and baculovirus-infected insect cells (with and without coexpressed cytochrome b5) were analysed by LC-MS. Enzyme kinetic parameters were estimated by nonlinear regression. Mean Km for the formation of 1?-hydroxymidazolam was 3-and 4-fold higher in T5-3A4 microsomes than in insect microsomes (pº0.05), with and without coexpressed cytochrome b5, respectively. Only minor differences in Vmax were observed and the higher Km in T5-3A4 microsomes was reflected by significantly lower Cl int compared to insect microsomes (pº0.001). For formation of 1?-hydroxymidazolam, human microsomes displayed Michaelis-Menten kinetics, while insect microsomes showed substrate inhibition kinetics. The different enzyme kinetics of midazolam observed in recombinant CYP3A4 microsomes from human and insect sources, especially the substantially higher Km obtained in human microsomes compared to insect microsomes, should be further evaluated since it may have implications for correlations to in vivo situation.
Introduction
In vitro technology is frequently used to characterize the metabolism of drug substances and their metabolites and such information is applied to predict metabolic clearance and potential drug-drug interactions in vivo. 1) Human liver microsomes (HLM) are often applied to study metabolism, but to study the metabolism of a drug via a specific cytochrome P450 (CYP) enzyme, recombinant microsomal preparations have become valuable in vitro systems. 2) Such c-DNA expressed systems include baculovirus-infected insect cells or membranes from E.coli. To convert the activity per unit enzyme in recombinant CYP systems to activity per mg protein in HLM, scaling factors like Relative Activity Factors (RAF) or Intersystem Extrapolation Factors (ISEF) should be used. 3) However, considerable variability in enzyme kinetic parameters has been observed in in vitro metabolism studies with recombinant CYP systems. 4) To more precisely scale up in vitro drug metabolism information to in vivo situation, there is a need for increased knowledge and understanding of factors leading to variability in observations. The importance of reconstitution of recombinant CYP expression systems with different cofactors has been extensively focused on recently. For example the presence of the electron donor protein cytochrome b5 has been identified as an important factor in in vitro metabolism studies and cDNA-expressed CYP enzyme activities have been reported to be affected by levels of coexpressed cytochrome b5.
5-7)
CYP3A4, the most abundant CYP enzyme in the human liver and intestine, is responsible for the metabolism of many therapeutic agents. 8, 9) The benzodiazepine midazolam (MDZ) is a well known CYP3A4 substrate and widely used as a probe substance for CYP3A4 activity. 10) Midazolam is metabolised to the main metabolite 1? -hydroxymidazolam (1?-OH MDZ) and a secondary metabolite 4-hydroxymidazolam (4-OH MDZ) (Fig. 1) .
11)
For several CYP3A4 substrates including midazolam atypical enzyme kinetics (positive or negative co-oper- ativity) have been reported in vitro. 7, 12) Whether this is an in vivo phenomena related to the properties of the enzyme itself or simply an in vitro artifact reflecting different experimental conditions, availability of electron donor proteins or differences in the enzyme active site between different recombinant sources are not known. 13) A two-site binding model for binding of CYP3A4 substrates to the active site of the enzyme has been proposed as a possible explanation for atypical enzyme kinetic observations. 8) For midazolam metabolism the results of different published studies seem to be rather inconsistent. Some report that CYP3A4-mediated metabolism of midazolam to 1?-OH MDZ exhibits substrate inhibition kinetics, 7, 14) whereas others observe classical hyperbolic Michaelis-Menten kinetics for the same reaction. [15] [16] [17] This study compares CYP3A4-mediated enzyme kinetics of midazolam in microsomes prepared from transfected human liver epithelial cells specifically expressing CYP3A4 (T5-3A4 clone) with enzyme kinetics in microsomes from baculovirus-infected insect cells with coexpressed cytochrome b5 (Supersomes TM ) and without cytochrome b5 (Xenosomes   TM   ) . Transfected human liver epithelial cell clones (THLE cells) were supplied by the Nestl á e Research Centre, Lausanne, Switzerland. Preparation of the cells from normal human hepatocytes is described elsewhere, but briefly cultured hepatocytes expressing trace or non-detectable CYP activity were immortalised by introduction of the simian virus 40 large tumour antigen gene. 18, 19) THLE clones expressing high specific CYP enzyme activity were obtained by subsequent transfection of CYP-DNA constructs. 18, 19) In the present experiments, a CYP3A4 subtransfected clone (T5-3A4) was used for isolation of microsomes expressing CYP3A4. The microsomes were prepared and isolated from T5-3A4 cells as earlier described, 20) but briefly the cell pellet was resuspended in hypotonic (0.05 M) sucrose solution and homogenised by tight fitting Dounce homogenisator. Subsequently, 445 mL hypertonic sucrose solution (2.5 M) was added to retrieve isotonic environment. The mixture was then centrifuged at 49 C in three subsequent steps, 10 minutes at 1700 g, (Hettich zentrifugen, Universal 32R), 10 minutes at 12 000 g (Beckman, Avanti J-25) and 60 minutes at 105 000 g (Sorvall Ultra Pro 80). The final pellet, containing the microsomes, was then homogenised in a buffer solution consisting of 10 mM HEPES, 2 mM EDTA and 0.25 M sucrose (200 mL per 12 mill cells). The microsome suspension was stored at -709 C. Determination of protein content in the microsome preparations was performed by the Bradford dyebinding procedure. 21) Immunoblotting: Concentration of CYP3A4 in the T5-3A4 microsomes was determined by immunoblotting assay using baculovirus-infected insect microsomes with spectrophotometric declared CYP3A4 content as the standard. hour and transferred to nitrocellulose membranes. The filters were blocked in T-TBS (10 mM Tris-HCl, pH 8.0, 150 mM NaCl) with 5% (w/v) low fat dry-milk and 0.05% Tween-20, followed by incubation overnight at 49 C with primary CYP3A4 antibodies (Dr. Rob Edwards, London). The secondary antibody, horseradish peroxidise-conjugated goat anti-rabbit IgG, was incubated in blocking solution for 1.5 hours. Immunoreactive bands were visualised with ECL Western blotting detection reagents (Amersham International). The membranes were transferred to a film cassette and exposed to film for 5 minutes (Geldoc).
Materials and methods

Chemicals
In vitro metabolism studies: Increasing midazolam concentrations (0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12.5, 15, 20, 25, 30, 40 and 50 mM) were preincubated at 379 C in 118 mM Tris-H2SO4 (pH 7.5), 0.5 mM MgSO4 and 1.6 mM NADPH for 5 minutes. The metabolism was initiated by adding preheated microsomes expressing human CYP3A4 (insect microsomes with or without coexpressed cytochrome b5, or T5-3A4 microsomes) and final concentrations of CYP3A4 were 1.9-3.9 nM (128-159 mg total protein in T5-3A4 and 7.0 and 10.3 mg protein in Supersomes TM and Xenosomes TM , respectively). Incubation volume was 220.5 mL and the samples were incubated for 7.5 minutes in glass containers in a 379 C shaking water bath. Incubation time and protein concentration applied were within the linear range and less than 20% midazolam was depleted after 7.5 minutes incubation time at 1 mM midazolam (data not shown). The incubation was terminated by adding 150 mL ice-cold acetonitrile including 0.044 mM diazepam as internal standard. After 30 minutes on ice, the samples were centrifuged at 5 min at 1600 g (3500 rpm) in Hettich sentrifuge at 49 C and the supernatant was analysed for 1?-OH MDZ and 4-OH MDZ formed. For each of the three different preparations the same batch of microsomes were used for all experiments (n＝3).
Determination of midazolam metabolites: The hydroxylated metabolites of MDZ, 1?-OH MDZ and 4-OH MDZ, were analysed by liquid chromatography with mass spectrometry detection (Shimadzu, Kyoto, Japan). Separation of the analytes was carried out on a reversed phase C8 column (50×3 mm, 5 mm; Inertsil, Varian, USA), using a gradient with two mobile phases; A: 0.05 M ammoniumformiat-buffer (pH 4.4) and B: acetonitrile 95%/methanol 5%. The relative contribution of mobile phase B increased linearly from 25% to 37.5% during the first five minutes after sample injection. This mobile phase solution was held constant for 2.5 minutes. During the following 2.5 minutes, mobile phase B content was increased to 46.7% and then quickly increased to 80%. From the 11 th to 17 th minute, the column was reequilibrated by reversing the mobile phase B to the start concentration of 25%. The flow rate of the mobile phase was 0.5 mL/min during analysis and 1 mL/min during reequilibration of the column. Analysis run time per sample was 17 minutes and retention times were 4.7 min for 4-OH MDZ and 5.7 min for 1?-OH MDZ. Diazepam (0.044 mM) was applied as the internal standard. For both metabolites intra-and inter-run accuracy and precision were satisfactory.
Data Analysis: Formation of 1?-OH MDZ and 4-OH MDZ by CYP3A4 were described using one of the following models: Michalis-Menten ( n＝ Vmax
One-way ANOVA was used to determine statistical differences in enzyme kinetic parameters for different microsomal preparations. When statistical significance was obtained (pº0.05), the unpaired Student's t-test was performed between groups. For pairwise tests Bonferroni correction was applied.
Results
Formation of 1?-hydroxymidazolam:
The recombinant CYP3A4 human microsomes showed different enzyme kinetics of midazolam than the insect microsomes. Estimated enzyme kinetic parameters for the formation of 1?-OH MDZ in the various microsomal preparations are listed in Table 1 . Mean Km for CYP3A4-mediated formation of 1?-OH MDZ were higher in T5-3A4 microsomes than in insect microsomes (pº0.001; Table 1 ), 5.6 mM in human microsomes versus 1.8 and 1.4 mM in insect microsomes with and without coexpressed cytochrome b5, respectively. Km in T5-3A4 microsomes was 3.0-and 4.1-fold higher than in the two insect microsomal preparations (p＝0.013 and 0.006), but there was no difference between Km for insect microsomes ( Table 1) . For Vmax the differences between human and insect microsomes were less pronounced. Mean Vmax were 9.7, 12.4 and 6.2 pmol/min/pmol CYP3A4 for T5-3A4 microsomes and insect microsomes with and without cytochrome b5, respectively (T5-3A4 vs. insect microsomes, p＝0.04 and 0.4; Table 1 ). Consequently a 3.8-and 2.5-fold higher intrinsic clearance was estimated in insect microsomes with and without coexpressed cytochrome b5, respectively, compared to in T5-3A4 microsomes (pº0.001; Table 1 ). For insect microsomes expressing CYP3A4 the presence of cytochrome b5 resulted in moderate increase in intrinsic clearance for 1?-OH MDZ formation (p＝0.027; Table 1 ). The largest differences between the human microsome preparation and insect microsomes were for estimated Km, while estimated Vmax for the three preparations showed minor differences. Thus, the 2.5-4-fold lower intrinsic clearance for T5-3A4 microsomes was largely due to increased Km. Dose-response curves for formation of 1?-OH MDZ by CYP3A4 with increasing concentration of midazolam in recombinant human liver microsomes (T5-3A4 microsomes) showed classical Michaelis-Menten kinetics (r 2 ＝ 0.99) (Fig. 2A) . In contrast, both CYP3A4 expressing insect microsomal preparations displayed substrate inhibition kinetics for the formation of this metabolite (best fit uncompetitive inhibition; r 2 ＝0.97), but the preparation with coexpressed cytochrome b5 showed less degree of substrate inhibition kinetics than the preparation without coexpressed cytochrome b5 (Figs. 2B and 2C) .
Formation of 4-hydroxymidazolam: Estimated kinetic parameters for the formation of 4-OH MDZ showed the same trend as the major metabolite, with lower estimated intrinsic clearance in T5-3A4 microsomes compared to insect microsomes (p＝0.042; Table  2 ). Also for 4-OH MDZ the largest differences between microsomal preparations were for the estimated Km ( Table 2) , and increased Km for 4-OH MDZ formation were mainly responsible for lower intrinsic clearance for T5-3A4 microsomes. It must, however, be kept in mind that greater uncertainties are associated with estimated enzyme kinetic parameters for 4-OH MDZ formation than for 1?-OH MDZ formation, since these curves barely reached or did not reach saturation (Fig. 3) .
None of the three microsomal preparations displayed substrate inhibition kinetics for the formation of the minor metabolite 4-OH MDZ (Fig. 3) . The best fit kinetic model for formation of 4-OH MDZ by T5-3A4 microsomes was the Michalis-Menten model ( 
＝0.99).
The ratios for intrinsic clearance of 1?-OH MDZ and 4-OH MDZ in the three microsomal preparations were comparable, i.e. 9.2, 9.6 and 7.8 for insect microsomes without and with coexpressed cytochrome b5, and T5-3A4, respectively.
Discussion
In the present study, CYP3A4-mediated enzyme kinetics of midazolam was compared in recombinant human liver microsomes (T5-3A4 microsomes) and baculovirusinfected insect cell microsomes. A significantly higher Km value was obtained in recombinant human microsomes than in insect microsomes for the formation of 1?-OH MDZ by CYP3A4. Only minor differences in Vmax were observed and the higher Km in T5-3A4 microsomes was reflected by a significantly lower Clint in these microsomes compared to insect microsomes. The same trend was noted for the secondary metabolite 4-OH MDZ. Identical incubation conditions and CYP3A4 levels were applied in the experiments, but there was higher total protein concentration in experiments with T5-3A4 microsomes. Thus, observed differences in Km could potentially reflect differences in non-specific binding. However, when Km values for 1?-OH MDZ obtained in the human microsomes were corrected for non-specific microsomal protein binding (applied literature value for free fraction of midazolam in microsomes with 1 mg/ml protein concentration (fumic＝0.7), which is substantially higher protein concentration than in incubations in the present study 23) ), Km in T5-3A4 microsomes were still significantly higher than Km in insect microsomes. Since Km reflects the affinity of the substrate to the enzyme, it is reasonable to believe that the observed differences may at least partly be due to conformational differences in the CYP3A4 enzyme in human and insect microsomal preparations. Interestingly, Houston and Kenworthy 13) have postulated that variability in kinetic behavior may be due to discreet differences in the enzyme active site between different recombinant sources. It has also earlier been reported that differences in membrane lipid compositions between in vitro systems may be a factor contributing to variable metabolism data between different laboratories and preparations. 5) In this respect it is interesting to note that similar Km, as found for recombinant human liver microsomes in the present study, was reported for 1?-OH MDZ formation in HLM. 24) Similar mean Km in HLM, based on results from several studies, has been reported by Proctor et al.
3)
As the T5-3A4 microsomes were derived from a human liver epithelial cell line, it might be speculated that they resemble human liver microsomes. However, metabolism studies with other CYP3A4 substrates should be performed to evaluate this further.
As discussed above, the 2.5-4-fold lower estimate of intrinsic clearance obtained in the present study for the formation of 1?-OH MDZ in T5-3A4 microsomes than in insect cell microsomes was primarily due to higher Km, since there were minor differences in Vmax. However, it should be mentioned that there is some insecurity in the Vmax estimates, as possible difference in holoprotein/ apoprotein ratio between the human and insect microsomes may lead to error in the estimation of active enzyme. It has recently been shown that there is discrepancy between spectrophotometric and immunological quantification of CYP enzymes. 25) Currently the holoprotein/apoprotein ratio in the T5-3A4 microsomes is not known.
The kinetic properties of drug metabolism by CYP enzymes are usually well described by the classical Michaelis-Menten model, but atypical enzyme kinetic behaviour has also been reported. 12) In the present study formation of 1?-OH MDZ by CYP3A4 in insect microsomes showed atypical enzyme kinetics, namely substrate inhibition, in accordance with previous reports. 7, 14) When identical incubation conditions were applied, this phenomenon was not observed in microsomes from CYP3A4 expressed human liver cells, where classical Michaelis-Menten kinetics was found for 1?-OH MDZ formation. For CYP3A4 it has been proposed that atypical kinetics may be explained by the ability of the enzyme to bind more than one drug molecule simultaneously or that there are co-operativity interactions at the active site. It is crucial to investigate whether such kinetics takes place in vivo or if these are in vitro effects, as this can result in incorrect estimates of intrinsic clearance and thus have consequences for in vivo predictions of clearance. 13, 26) With respect to the observed substrate inhibition curves for formation of 1?-OH MDZ in CYP3A4 expressed insect microsomes obtained in the present study and by others, 7, 14, 27) some authors have reported a hyperbolic curve shape for formation of this metabolite in microsomes from insect and E.coli cells. [15] [16] [17] The apparent discordance in CYP3A experimental data has earlier been postulated to be due to both a variable source of CYP3A enzymes and differences in buffer, salt composition and components of the NADPH-regenerating system used for incubation. 16, 20, 27) However, it must be kept in mind that identical incubation conditions, apart from total protein concentration, have been applied in the human and insect microsomal experiments in the present study, which revealed classical and atypical enzyme kinetics, respectively, for the formation of 1?-OH MDZ.
As recombinant CYP expression systems are artificial, it has been argued that such systems need to be reconstituted with various cofactors. Recently the presence of the electron donor protein cytochrome b5 has been identified as an important factor in in vitro metabolism studies and cDNA-expressed CYP3A4 activitiy has been reported affected by levels of coexpressed cytochrome b5.
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In the present study, both insect microsomes with and without coexpressed cytochrome b5 showed substrate inhibition kinetics and about 3-4-fold higher Clint compared to the human microsomes. In agreement with several other reports the presence of cytochrome b5 significantly increased the rate of metabolism of midazolam in baculovirus-infected insect cell microsomes. 16, 28) We do not know whether T5-3A4 microsomes express cytochrome b5, because we were unable to quantify cytochrome b5 in these microsomes. However, coexpressed cytochrome b5 in the insect microsomes cannot explain the observed differences in enzyme kinetics observed in the present study between human and insect microsomes, even if the presence of cytochrome b5 in insect microsomes decreased the level of substrate inhibiton to a certain degree. Thus, other factors that might differ between the two systems, e.g. membrane composition as discussed above, may be important contributors to the different enzyme kinetics found here.
In conclusion, a CYP3A4-expressing recombinant human liver microsomal preparation showed significantly higher Km for the formation of 1?-hydroxymidazolam than baculovirus-infected insect cell microsomes. Consequently estimated intrinsic clearance for 1?-OH MDZ was substantially lower in human microsomes than in insect microsomes. The CYP3A4 enzyme kinetic pattern was different between microsomes from human and insect sources. This should be further evaluated, as it may have implications for correlations of drug metabolism to in vivo situation.
